Valiant Laboratories: Reg 74(5) Certificate for Q4FY26 - No Dematerialization Requests
Valiant Laboratories Limited received a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The RTA confirmed the regulation's non-applicability as all securities are in dematerialized form, with no dematerialization requests received.
This is a routine regulatory compliance filing. The confirmation that no dematerialization requests were received is standard procedure and has no material impact on the company's operations or financials.
The announcement is a routine regulatory filing confirming that no dematerialization requests were received, which is a standard compliance procedure and does not inherently indicate positive or negative news.
Valiant Laboratories Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate was received from MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent.
According to the confirmation from MUFG Intime India Private Limited, Regulation 74(5) is not applicable to Valiant Laboratories Limited as all its securities are held in dematerialized form. No requests for dematerialization, mutilation, or cancellation of securities were received by the company or its RTA during the aforementioned quarter.
The company has also uploaded this intimation on its official website, www.valiantlabs.in.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.